Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade.
Date
2021-10-18ICR Author
Author
Appleton, E
Hassan, J
Chan Wah Hak, C
Sivamanoharan, N
Wilkins, A
Samson, A
Ono, M
Harrington, KJ
Melcher, A
Wennerberg, E
Type
Journal Article
Metadata
Show full item recordAbstract
Cancer patients with low or absent pre-existing anti-tumour immunity ("cold" tumours) respond poorly to treatment with immune checkpoint inhibitors (ICPI). In order to render these patients susceptible to ICPI, initiation of de novo tumour-targeted immune responses is required. This involves triggering of inflammatory signalling, innate immune activation including recruitment and stimulation of dendritic cells (DCs), and ultimately priming of tumour-specific T cells. The ability of tumour localised therapies to trigger these pathways and act as in situ tumour vaccines is being increasingly explored, with the aspiration of developing combination strategies with ICPI that could generate long-lasting responses. In this effort, it is crucial to consider how therapy-induced changes in the tumour microenvironment (TME) act both as immune stimulants but also, in some cases, exacerbate immune resistance mechanisms. Increasingly refined immune monitoring in pre-clinical studies and analysis of on-treatment biopsies from clinical trials have provided insight into therapy-induced biomarkers of response, as well as actionable targets for optimal synergy between localised therapies and ICB. Here, we review studies on the immunomodulatory effects of novel and experimental localised therapies, as well as the re-evaluation of established therapies, such as radiotherapy, as immune adjuvants with a focus on ICPI combinations.
Collections
Subject
immune checkpoint inhibitors
immunosuppression
oncolytic virus
radiotherapy
tumor microenvionment
Adjuvants, Immunologic
Animals
Antigens, Neoplasm
Cancer Vaccines
Combined Modality Therapy
Dendritic Cells
Drug Screening Assays, Antitumor
Drug Synergism
Herpesvirus 1, Human
Humans
Immune Checkpoint Inhibitors
Immunity, Innate
Immunomodulating Agents
Immunomodulation
Immunotherapy
Mice
Neoplasms
Oncolytic Virotherapy
T-Lymphocyte Subsets
Tumor Microenvironment
Research team
Targeted Therapy
Trans Immunotherapy
Language
eng
Date accepted
2021-09-29
License start date
2021-10-18
Citation
Frontiers in Immunology, 2021, 12 pp. 754436 -
Publisher
FRONTIERS MEDIA SA
Except where otherwise noted, this item's license is described
as
http://creativecommons.org/licenses/by/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome".
Spain, L; Larkin, J; Martin-Liberal, J (SPRINGER, 2016-06-01) -
The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation.
Humphries, MP; Craig, SG; Kacprzyk, R; Fisher, NC; Bingham, V; et al. (BMC, 2020-06-01)BACKGROUND: Limited studies examine the immune landscape in Esophageal Adenocarcinoma (EAC). We aim to identify novel associations, which may inform immunotherapy treatment stratification. METHODS: Three hundred twenty-nine ... -
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Haanen, J; Ernstoff, M; Wang, Y; Menzies, A; Puzanov, I; et al. (BMJ PUBLISHING GROUP, 2020-01-01)Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events (irAEs) during therapy with immune checkpoint inhibitors are at risk for developing severe toxicities again on rechallenge with checkpoint ...